Armata Pharmaceuticals Announces Clearance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis

/in ,

Link to full article Feb. 22, 2022 Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared Armata’s Investigational New Drug (IND) application to initiate a clinical trial of […]

Read more

Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company’s Bacteriophage Development

/in ,

Link to full article Feb. 9, 2022 Armata intends to use the net proceeds from this transaction to advance its clinical pipeline and strengthen its bacteriophage platform. The clinical pipeline is led by AP-PA02, currently under evaluation in the ‘SWARM-P.a.‘ trial as a novel therapeutic to treat chronic Pseudomonas aeruginosa infections in people with cystic fibrosis. A […]

Read more

Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs

/in ,

Link to full article Enhanced AP-PA02 enters SWARM-P.a. study AP-PA02 identified as lead cocktail for non-cystic fibrosis bronchiectasis Phase 2 trial Distinct phage cocktail (AP-PA03) for pneumonia advances to manufacturing Jan. 5, 2022 The improvements in AP-PA02 reflect Armata’s core strategy of utilizing clinical isolate surveillance data to drive enhancement of product composition. Prior to […]

Read more

Armata Pharmaceuticals Provides Regulatory and Clinical Update Reflecting Sustained Progress Across Key Phage Therapeutic Development Programs

/in ,

Link to full article Nov. 18, 2021 Announces FDA clearance of IND to initiate Phase 1b/2a clinical trial of AP-SA02 in Staphylococcus aureus bacteremia (“diSArm” Study) Achieves significant milestone under previously announced therapeutic development award from the Cystic Fibrosis Foundation for continued advancement of Phase 1b/2a SWARM-P.a. clinical trial of AP-PA02 in Pseudomonas aeruginosa infections […]

Read more

Cystic Fibrosis Foundation Makes Equity Investment in Armata Pharmaceuticals

/in ,

Link to full article Funds to be used to further advance development of lead candidate AP-PA02, which is being evaluated in a Phase 1b/2a clinical trial in Pseudomonas aeruginosa respiratory infections in CF patients Innoviva, a significant Armata shareholder, also elected to participate Oct. 28, 2021 In accordance with the terms of the investment agreement, […]

Read more

Adherium submits US FDA 510(k) application for Ellipta® inhaler users to connect to Hailie platform with physiological parameters

/in ,

Link to full article Melbourne, Australia – 7 March 2022: Adherium (ASX: ADR), a leader in respiratory eHealth, remote monitoring, and data management solutions, announces the submission to the US Food and Drug Administration (FDA) of a 510(k) clearance to market application to connect Ellipta® inhaler users with its new, next generation Hailie® sensor with […]

Read more

Adherium announces the appointment of Lou Panaccio to the Board with Matt McNamara stepping down

/in ,

Link to Full Article Melbourne, Australia – 25 February 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a provider of integrated digital health solutions and a world leader in connected respiratory medical devices, announces the appointment of Mr Lou Panaccio as a Non-executive director of Adherium with Mr Matthew McNamara stepping down as a […]

Read more

Manufacturing started for Hailie® for Symbicort® sensors with physiological parameters

/in ,

Link to article Melbourne, Australia – 11 February 2022: Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, is pleased to announce it has completed the first production run of the next generation Hailie® sensors with physiological parameters for monitoring Asthma and Chronic Obstructive Pulmonary Disease (COPD) medication use. […]

Read more

$25m spur for vital bio-med projects

/in , , ,

Biomedical projects at the cutting edge of innovation will receive a $25m cash injection, in a boost for next-gen medicine including stem cell research, new treatments for autism and a technology that allows medicine to be taken through the skin. The $25m investment through the federal Biomedical Translation Fund will potentially benefit thousands of Australians […]

Read more

AUSSIE-BACKED “SMART KNEE” TECHNOLOGY TO HIT THE GROUND RUNNING IN THE US MARKET

/in , ,

An Australian backed and enabled “smart” orthopaedic knee implant set to revolutionise knee replacements has been given marketing authorisation by the US Food and Drug Administration. The canturioTMte device has been backed by Melbourne-based healthcare investment firm, BioScience Managers (BSM) to assist with the aggregation of patient data for software developed by Melbourne-based healthcare informatics […]

Read more